

CaSP: Inclusion & Exclusion Criteria

Inclusion Criteria

Patients must fulfil all of the following criteria to be eligible for this study.

- I. Male or female patients, aged 16 years and older, with pathologically confirmed incurable, advanced and/or metastatic tumour of any histologic type or an earlier diagnosis of a poor prognosis tumour;
- II. Life expectancy of equal to or greater than 3 months;
- III. Sufficient and accessible tissue for molecular screening;
- IV. ECOG performance status 0, 1 or 2;
- V. Willingness to comply with all protocol requirements, including long-term follow-up, and instructions from study staff;
- VI. Patients with primary central nervous system (CNS) tumours, with stable neurological function, on stable doses of steroids/anti-epileptics over at least a 4-week period are eligible; and
- VII. Provide written informed consent

Exclusion Criteria

Patients with any one of the following characteristics will not be eligible for this study.

- I. Co-morbidities or conditions that may compromise assessment of key outcomes or in the opinion of the clinician, limit the ability of the patient to comply with the protocol;
- II. For non-central nervous system (CNS) cancers, patients with symptomatic CNS involvement of his/her cancer are excluded.
- III. History of another malignancy within 2 years prior to consent are excluded unless adequately treated and determined free of progressive and metastatic disease for at least 6 months.

